AMENDMENTS TO THE CLAIMS

Claim 1. (Currently amended) A compound which conforms to the general formula I:



I

Wherein

W represents a 5 to 7 atoms cycloalkyl or heterocycloalkyl ring;

R_1 and R_2 represent independently hydrogen, C_1-C_6-alkyl, C_2-C_6-alkenyl, C_2-C_6-alkynyl, arylalkyl, heteroarylalkyl, hydroxy, amino, aminoalkyl, hydroxyalkyl, C_1-C_6-alkoxy or R_1 and R_2 together can form a C_3-C_7-cycloalkyl ring, a carbonyl bond C=O or a carbon double bond;

P and Q are each independently selected and denote a cycloalkyl, an aryl or heteroaryl group of formula











R_3, R_4, R_5, R_6, and R_7 independently are hydrogen, halogen, -CN, nitro, C_1-C_6-alkyl, C_3-C_6-cycloalkyl, C_3-C_7-cycloalkylalkyl, C_2-C_6-alkenyl, C_2-C_6-alkynyl, halo-C_1-C_6-alkyl, -heteroaryl, heteroarylalkyl, arylalkyl, aryl, $-OR_8$, $-NR_8R_9$, $-C(=NR_{10})NR_8R_9$, $N(=NR_{10})NR_8R_9$, $-NR_8COR_9$, $NR_8CO_2R_9$, $NR_8SO_2R_9$, $-NR_{10}CO\ NR_8R_9$, $-SR_8$, $-S(=O)R_8$, $-S(=O)_2R_8$, $-S(=O)_2NR_8R_9$, $-C(=O)R_8$, ~~$-C(=O)_2R_8$,~~ $-C(=O)NR_8R_9$, $-C(=NR_8)R_9$, or $C(=NOR_8)R_9$ substituents; wherein optionally two substituents are combined to the intervening atoms to form a bicyclic heterocycloalkyl, aryl or

heteroaryl ring; wherein each ring is optionally further substituted with 1-5 independent halogen, -CN, C_1-C_6-alkyl, -O(C_0-C_6-alkyl), -O(C_3-C_7-cycloalkylalkyl), -O(aryl), -O(heteroaryl), -O(C_1-C_3-alkylaryl), -O(C_1-C_3-alkylheteroaryl), –N(C_0-C_6-alkyl)(C_0-C_3-alkylaryl) or –N(C_0-C_6-alkyl)(C_0-C_3-alkylheteroaryl) groups;

R_8, R_9, R_{10} each independently is hydrogen, C_1-C_6-alkyl, C_3-C_6-cycloalkyl, C_3-C_7-cycloalkylalkyl, C_2-C_6-alkenyl, C_2-C_6-alkynyl, halo-C_1-C_6-alkyl, heterocycloalkyl, heteroaryl, heteroarylalkyl, arylalkyl or aryl; any of which is optionally substituted with 1-5 independent halogen, -CN, C_1-C_6-alkyl, -O(C_0-C_6-alkyl), -O(C_3-C_7-cycloalkylalkyl), -O(aryl), -O(heteroaryl), -N(C_0-C_6-alkyl)(C_0-C_6-alkyl),-N(C_0-C_6-alkyl)(C_3-C_7-cycloalkyl) or –N(C_0-C_6-alkyl)(aryl) substituents;

D, E, F, G and H represent independently –C(R_3)=, –C(R_3)=C(R_4)-,-C(=O)-,-C(=S)-, –O-, -N=, -N(R_3)- or -S-;

A is azo –N=N-, ethyl, ethenyl, ethynyl, -NR_8C(=O)-, NR_8S(=O)$_2$-, -C(=O)NR_8-, -S-, -S(=O)-, -S(=O)$_2$-, -S(=O)$_2$$NR_8$-, -C(=O)-O-, -O-C(=O)-, -C(=NR_8)NR_9-, C(=NOR_8)NR_9- , -NR_8C(=NOR_9)-, =N-O-, -O-N=CH- or a group aryl or heteroaryl of formula












R_3, R_4, R_5 and R_6 independently are as defined above;
D, E, F, G and H independently represent a carbon group, oxygen, nitrogen, sulphur or a double bond;

B represents a single bond, -C(=O)-C_0-C_2-alkyl-, -C(=O)-C_2-C_6-alkenyl-, -C(=O)-C_2-C_6-alkynyl-, -C(=O)-O-, -C(=O)NR_8-C_0-C_2-alkyl-, -C(=NR_8)NR_9-S(=O)-C_0-C_2-

alkyl-, $-S(=O)_2-C_0-C_2$-alkyl-, $-S(=O)_2NR_8-C_0-C_2$-alkyl-, $C(=NR_8)-C_0-C_2$-alkyl-, $-C(=NOR_8)-C_0-C_2$-alkyl- or $-C(=NOR_8)NR_9-C_0-C_2$-alkyl-;
R_8 and R_9, independently are as defined above;

any N may be an N-oxide;

or pharmaceutically acceptable salts, hydrates or solvates of such compounds

but excluding the following compounds

4-(3-phenyl-oxadiazol-5-yl)-N-(4-bromophenyl)aminocarbonylpiperidine
N-benzoyl-3-(3,4-dimethoxyphenylaminocarbonyl)-piperidin-4-one
N-(3-cyanophenytlmethylcarbonyl)-4-(3-(2,3-dichlorophenyl)-pyrazo-5-yl)piperidine.

Claim 2. (Currently amended) A compound according to claim 1 having the formula I-A



I-A

Wherein

R_1 and R_2 represent independently hydrogen, C_1-C_6-alkyl, C_2-C_6-alkenyl, C_2-C_6-alkynyl, arylalkyl, heteroarylalkyl, hydroxy, amino, aminoalkyl, hydroxyalkyl, C_1-C_6-alkoxy or R_1 and R_2 together can form a C_3-C_7-cycloalkyl ring, a carbonyl bond C=O or a carbon double bond;

P and Q are each independently selected and denote a cycloalkyl, an aryl or heteroaryl group of formula



R_3, R_4, R_5, R_6, and R_7 independently are hydrogen, halogen, -CN, nitro, C_1-C_6-alkyl, C_3-C_6-cycloalkyl, C_3-C_7-cycloalkylalkyl, C_2-C_6-alkenyl, C_2-C_6-alkynyl, halo-C_1-C_6-alkyl, -heteroaryl, heteroarylalkyl, arylalkyl, aryl, -OR_8, -NR_8R_9, -$C(=NR_{10})NR_8R_9$, $N(=NR_{10})NR_8R_9$, -NR_8COR_9, $NR_8CO_2R_9$, $NR_8SO_2R_9$, -$NR_{10}CO$ NR_8R_9, -SR_8, -$S(=O)R_8$, -$S(=O)_2R_8$, -$S(=O)_2NR_8R_9$, -$C(=O)R_8$, ~~-$C(=O)_2R_8$,~~ -$C(=O)NR_8R_9$, -$C(=NR_8)R_9$, or $C(=NOR_8)R_9$ substituents; wherein optionally two substituents are combined to the intervening atoms to form a bicyclic heterocycloalkyl, aryl or heteroaryl ring; wherein each ring is optionally further substituted with 1-5 independent halogen, -CN, C_1-C_6-alkyl, -$O(C_0$-C_6-alkyl), -$O(C_3$-C_7-cycloalkylalkyl), -O(aryl), -O(heteroaryl), -$O(C_1$-C_3-alkylaryl), -$O(C_1$-C_3-alkylheteroaryl), –$N(C_0$-C_6-alkyl)(C_0-C_3-alkylaryl) or –$N(C_0$-C_6-alkyl)(C_0-C_3-alkylheteroaryl) groups;

R_8, R_9, R_{10} each independently is hydrogen, C_1-C_6-alkyl, C_3-C_6-cycloalkyl, C_3-C_7-cycloalkylalkyl, C_2-C_6-alkenyl, C_2-C_6-alkynyl, halo-C_1-C_6-alkyl, heterocycloalkyl, heteroaryl, heteroarylalkyl, arylalkyl or aryl; any of which is optionally substituted with 1-5 independent halogen, -CN, C_1-C_6-alkyl, -$O(C_0$-C_6-alkyl), -$O(C_3$-C_7-cycloalkylalkyl), -O(aryl), -O(heteroaryl), -$N(C_0$-C_6-alkyl)(C_0-C_6-alkyl),-$N(C_0$-C_6-alkyl)(C_3-C_7-cycloalkyl) or –$N(C_0$-C_6-alkyl)(aryl) substituents;

D, E, F, G and H represent independently –$C(R_3)$=, –$C(R_3)=C(R_4)$-,-C(=O)-,-C(=S)-, –O-, -N=, -$N(R_3)$- or -S-;

A is azo –N=N-, ethyl, ethenyl, ethynyl, -$NR_8C(=O)$-, $NR_8S(=O)_2$-, -$C(=O)NR_8$-, -S-, -S(=O)-, -$S(=O)_2$-, -$S(=O)_2NR_8$-, -C(=O)-O-, -O-C(=O)-, -$C(=NR_8)NR_9$-, $C(=NOR_8)NR_9$- , -$NR_8C(=NOR_9)$-, =N-O-, -O-N=CH- or a group aryl or heteroaryl of formula



R_3, R_4, R_5 and R_6 independently are as defined above;
D, E, F, G and H independently represent a carbon group, oxygen, nitrogen, sulphur or a double bond;

B represents a single bond, -C(=O)-C_2-C_6-alkenyl-, -C(=O)-C_2-C_6-alkynyl-, -C(=O)-C_0-C_2-alkyl-, C(=O)-O-, -C(=O)NR_8-C_0-C_2-alkyl-, -C(=NR_8)NR_9-S(=O)-C_0-C_2-alkyl-, -S(=O)$_2$-C_0-C_2-alkyl-, -S(=O)$_2$$NR_8$-$C_0$-$C_2$-alkyl-, C(=$NR_8$)-$C_0$-$C_2$-alkyl-, -C(=$NOR_8$)-$C_0$-$C_2$-alkyl- or -C(=$NOR_8$)$NR_9$-$C_0$-$C_2$-alkyl-;
R_8 and R_9, independently are as defined above;

Any N may be an N-oxide.

or pharmaceutically acceptable salts, hydrates or solvates of such compounds.

Claim 3. (Currently amended) A compound according to claim 1 or 2 having the formula I-B



Wherein

R_1 and R_2 represent independently hydrogen, C_1-C_6-alkyl, C_2-C_6-alkenyl, C_2-C_6-alkynyl, arylalkyl, heteroarylalkyl, hydroxy, amino, aminoalkyl, hydroxyalkyl, C_1-C_6-alkoxy

or R_1 and R_2 together can form a C_3-C_7-cycloalkyl ring, a carbonyl bond C=O or a carbon double bond;

P and Q are each independently selected and denote a cycloalkyl, an aryl or heteroaryl group of formula







R_3, R_4, R_5, R_6, and R_7 independently are hydrogen, halogen, -CN, nitro, C_1-C_6-alkyl, C_3-C_6-cycloalkyl, C_3-C_7-cycloalkylalkyl, C_2-C_6-alkenyl, C_2-C_6-alkynyl, halo-C_1-C_6-alkyl, -heteroaryl, heteroarylalkyl, arylalkyl, aryl, -OR_8, -NR_8R_9, -$C(=NR_{10})NR_8R_9$, $N(=NR_{10})NR_8R_9$, -NR_8COR_9, $NR_8CO_2R_9$, $NR_8SO_2R_9$, -$NR_{10}CO\ NR_8R_9$, -SR_8, -$S(=O)R_8$, -$S(=O)_2R_8$, -$S(=O)_2NR_8R_9$, -$C(=O)R_8$, ~~-$C(=O)_2R_8$,~~ -$C(=O)NR_8R_9$, -$C(=NR_8)R_9$, or $C(=NOR_8)R_9$ substituents; wherein optionally two substituents are combined to the intervening atoms to form a bicyclic heterocycloalkyl, aryl or heteroaryl ring; wherein each ring is optionally further substituted with 1-5 independent halogen, -CN, C_1-C_6-alkyl, -$O(C_0$-C_6-alkyl), -$O(C_3$-C_7-cycloalkylalkyl), -O(aryl), -O(heteroaryl), -$O(C_1$-C_3-alkylaryl), -$O(C_1$-C_3-alkylheteroaryl), –$N(C_0$-C_6-alkyl)(C_0-C_3-alkylaryl) or –$N(C_0$-C_6-alkyl)(C_0-C_3-alkylheteroaryl) groups;

R_8, R_9, R_{10} each independently is hydrogen, C_1-C_6-alkyl, C_3-C_6-cycloalkyl, C_3-C_7-cycloalkylalkyl, C_2-C_6-alkenyl, C_2-C_6-alkynyl, halo-C_1-C_6-alkyl, heterocycloalkyl, heteroaryl, heteroarylalkyl, arylalkyl or aryl; any of which is optionally substituted with 1-5 independent halogen, -CN, C_1-C_6-alkyl, -$O(C_0$-C_6-alkyl), -$O(C_3$-C_7-cycloalkylalkyl), -O(aryl), -O(heteroaryl), -$N(C_0$-C_6-alkyl)(C_0-C_6-alkyl),-$N(C_0$-C_6-alkyl)(C_3-C_7-cycloalkyl) or –$N(C_0$-C_6-alkyl)(aryl) substituents;

D, E, F, G and H in P & Q represent independently –$C(R_3)$=, –$C(R_3)=C(R_4)$-,-C(=O)-,-C(=S)-, –O-, -N=, -$N(R_3)$- or -S-;

D, E and G in A independently are as defined for A in claim 1;

B represents a single bond, -C(=O)-C_0-C_2-alkyl-, -C(=O)-C_2-C_6-alkenyl-, -C(=O)-C_2-C_6-alkynyl-, -C(=O)-O-, -C(=O)NR_8-C_0-C_2-alkyl-, -C(=NR_8)NR_9-S(=O)-C_0-C_2-alkyl-, -S(=O)$_2$-C_0-C_2-alkyl-, -S(=O)$_2$$NR_8$-$C_0$-$C_2$-alkyl-, C(=$NR_8$)-$C_0$-$C_2$-alkyl-, -C(=$NOR_8$)-$C_0$-$C_2$-alkyl- or -C(=$NOR_8$)$NR_9$-$C_0$-$C_2$-alkyl-;
R_8 and R_9, independently are as defined above;

Any N may be an N-oxide.

or pharmaceutically acceptable salts, hydrates or solvates of such compounds.

Claim 4. (Currently amended) A compound according to claim 1 or 2 having the formula I-C



Wherein

R_1 and R_2 represent independently hydrogen, C_1-C_6-alkyl, C_2-C_6-alkenyl, C_2-C_6-alkynyl, arylalkyl, heteroarylalkyl, hydroxy, hydroxyalkyl, C_1-C_6-alkoxy or R_1 and R_2 together can form a carbonyl bond C=O or a carbon double bond;

P and Q are each independently selected and denote a cycloalkyl, an aryl or heteroaryl group of formula



R_3, R_4, R_5, R_6, and R_7 independently are hydrogen, halogen, -CN, nitro, C_1-C_6-alkyl, C_3-C_6-cycloalkyl, C_3-C_7-cycloalkylalkyl, C_2-C_6-alkenyl, C_2-C_6-alkynyl, halo-C_1-C_6-alkyl, -heteroaryl, heteroarylalkyl, arylalkyl, aryl, -OR_8, -NR_8R_9, -C(=NR_{10})NR_8R_9,

$N(=NR_{10})NR_8R_9$, $-NR_8COR_9$, $NR_8CO_2R_9$, $NR_8SO_2R_9$, $-NR_{10}CO\ NR_8R_9$, $-SR_8$, $-S(=O)R_8$, $-S(=O)_2R_8$, $-S(=O)_2NR_8R_9$, $-C(=O)R_8$, ~~$-C(=O)_2R_8$~~, $-C(=O)NR_8R_9$, $-C(=NR_8)R_9$, or $C(=NOR_8)R_9$ substituents; wherein optionally two substituents are combined to the intervening atoms to form a bicyclic heterocycloalkyl, aryl or heteroaryl ring; wherein each ring is optionally further substituted with 1-5 independent halogen, -CN, C_1-C_6-alkyl, $-O(C_0$-C_6-alkyl), $-O(C_3$-C_7-cycloalkylalkyl), -O(aryl), -O(heteroaryl), $-O(C_1$-C_3-alkylaryl), $-O(C_1$-C_3-alkylheteroaryl), $-N(C_0$-C_6-alkyl)(C_0-C_3-alkylaryl) or $-N(C_0$-C_6-alkyl)(C_0-C_3-alkylheteroaryl) groups;

R_8, R_9, R_{10} each independently is hydrogen, C_1-C_6-alkyl, C_3-C_6-cycloalkyl, C_3-C_7-cycloalkylalkyl, C_2-C_6-alkenyl, C_2-C_6-alkynyl, halo-C_1-C_6-alkyl, heterocycloalkyl, heteroaryl, heteroarylalkyl, arylalkyl or aryl; any of which is optionally substituted with 1-5 independent halogen, -CN, C_1-C_6-alkyl, $-O(C_0$-C_6-alkyl), $-O(C_3$-C_7-cycloalkylalkyl), -O(aryl), -O(heteroaryl), $-N(C_0$-C_6-alkyl)(C_0-C_6-alkyl),$-N(C_0$-C_6-alkyl)(C_3-C_7-cycloalkyl) or $-N(C_0$-C_6-alkyl)(aryl) substituents;

D, E, F, G and H represent independently $-C(R_3)=$, $-C(R_3)=C(R_4)-$,$-C(=O)-$,$-C(=S)-$, $-O-$, $-N=$, $-N(R_3)-$ or $-S-$;

B represents a single bond, $-C(=O)-C_0$-C_2-alkyl-, $-C(=O)-C_2$-C_6-alkenyl-, $-C(=O)-C_2$-C_6-alkynyl-, $-C(=O)-O-$, $-C(=O)NR_8-C_0$-C_2-alkyl-, $-C(=NR_8)NR_9-S(=O)-C_0$-C_2-alkyl-$-S(=O)_2-C_0$-C_2-alkyl-, $-S(=O)_2NR_8-C_0$-C_2-alkyl-, $C(=NR_8)-C_0$-C_2-alkyl-, $-C(=NOR_8)-C_0$-C_2-alkyl- or $-C(=NOR_8)NR_9-C_0$-C_2-alkyl-;
R_8 and R_9, independently are as defined above;

Any N may be an N-oxide.

or pharmaceutically acceptable salts, hydrates or solvates of such compounds.

Claim 5. (Currently amended) A compound according to claim 1 or 2 having the formula I-D



I-D

Wherein

P and Q are each independently selected and denote a cycloalkyl, an aryl or heteroaryl group of formula



R_3, R_4, R_5, R_6, and R_7 independently are hydrogen, halogen, -CN, nitro, C_1-C_6-alkyl, C_3-C_6-cycloalkyl, C_3-C_7-cycloalkylalkyl, C_2-C_6-alkenyl, C_2-C_6-alkynyl, halo-C_1-C_6-alkyl, -heteroaryl, heteroarylalkyl, arylalkyl, aryl, -OR_8, -NR_8R_9, -$C(=NR_{10})NR_8R_9$, $N(=NR_{10})NR_8R_9$, -NR_8COR_9, $NR_8CO_2R_9$, $NR_8SO_2R_9$, -$NR_{10}CO$ NR_8R_9, -SR_8, -$S(=O)R_8$, -$S(=O)_2R_8$, -$S(=O)_2NR_8R_9$, -$C(=O)R_8$, ~~-$C(=O)_2R_8$,~~ -$C(=O)NR_8R_9$, -$C(=NR_8)R_9$, or $C(=NOR_8)R_9$ substituents; wherein optionally two substituents are combined to the intervening atoms to form a bicyclic heterocycloalkyl, aryl or heteroaryl ring; wherein each ring is optionally further substituted with 1-5 independent halogen, -CN, C_1-C_6-alkyl, -$O(C_0$-C_6-alkyl), -$O(C_3$-C_7-cycloalkylalkyl), -O(aryl), -O(heteroaryl), -$O(C_1$-C_3-alkylaryl), -$O(C_1$-C_3-alkylheteroaryl), –$N(C_0$-C_6-alkyl)(C_0-C_3-alkylaryl) or –$N(C_0$-C_6-alkyl)(C_0-C_3-alkylheteroaryl) groups;

R_8, R_9, R_{10} each independently is hydrogen, C_1-C_6-alkyl, C_3-C_6-cycloalkyl, C_3-C_7-cycloalkylalkyl, C_2-C_6-alkenyl, C_2-C_6-alkynyl, halo-C_1-C_6-alkyl, heterocycloalkyl, heteroaryl, heteroarylalkyl, arylalkyl or aryl; any of which is optionally substituted with 1-5 independent halogen, -CN, C_1-C_6-alkyl, -$O(C_0$-C_6-alkyl), -$O(C_3$-C_7-cycloalkylalkyl), -O(aryl), -O(heteroaryl), -$N(C_0$-C_6-alkyl)(C_0-C_6-alkyl),-$N(C_0$-C_6-alkyl)(C_3-C_7-cycloalkyl) or –$N(C_0$-C_6-alkyl)(aryl) substituents;

D, E, F, G and H represent independently –C(R_3)=, –C(R_3)=C(R_4)-,-C(=O)-,-C(=S)-, –O-, -N=, -N(R_3)- or -S-;

Any N may be an N-oxide.

or pharmaceutically acceptable salts, hydrates or solvates of such compounds.

Claim 6. (Currently amended) A compound according to claim 1 or 2 having the formula I-E



I-E

Wherein

P and Q are each independently selected and denote a cycloalkyl, an aryl or heteroaryl group of formula



,


,


,


,


R_3, R_4, R_5, R_6, and R_7 independently are hydrogen, halogen, -CN, nitro, C_1-C_6-alkyl, C_3-C_6-cycloalkyl, C_3-C_7-cycloalkylalkyl, C_2-C_6-alkenyl, C_2-C_6-alkynyl, halo-C_1-C_6-alkyl, -heteroaryl, heteroarylalkyl, arylalkyl, aryl, -OR_8, -NR_8R_9, -C(=NR_{10})NR_8R_9, N(=NR_{10})NR_8R_9, -NR_8COR_9, $NR_8CO_2R_9$, $NR_8SO_2R_9$, -$NR_{10}CO$ NR_8R_9, -SR_8, -S(=O)R_8, -S(=O)$_2R_8$, -S(=O)$_2NR_8R_9$, -C(=O)R_8, ~~-C(=O)$_2R_8$,~~ -C(=O)NR_8R_9, -C(=NR_8)R_9, or C(=NOR_8)R_9 substituents; wherein optionally two substituents are combined to the intervening atoms to form a bicyclic heterocycloalkyl, aryl or heteroaryl ring; wherein each ring is optionally further substituted with 1-5 independent halogen, -CN, C_1-C_6-alkyl, -O(C_0-C_6-alkyl), -O(C_3-C_7-cycloalkylalkyl),

-O(aryl), -O(heteroaryl), -O(C_1-C_3-alkylaryl), -O(C_1-C_3-alkylheteroaryl), –N(C_0-C_6-alkyl)(C_0-C_3-alkylaryl) or –N(C_0-C_6-alkyl)(C_0-C_3-alkylheteroaryl) groups;

R_8, R_9, R_{10} each independently is hydrogen, C_1-C_6-alkyl, C_3-C_6-cycloalkyl, C_3-C_7-cycloalkylalkyl, C_2-C_6-alkenyl, C_2-C_6-alkynyl, halo-C_1-C_6-alkyl, heterocycloalkyl, heteroaryl, heteroarylalkyl, arylalkyl or aryl; any of which is optionally substituted with 1-5 independent halogen, -CN, C_1-C_6-alkyl, -O(C_0-C_6-alkyl), -O(C_3-C_7-cycloalkylalkyl), -O(aryl), -O(heteroaryl), -N(C_0-C_6-alkyl)(C_0-C_6-alkyl),-N(C_0-C_6-alkyl)(C_3-C_7-cycloalkyl) or –N(C_0-C_6-alkyl)(aryl) substituents;

D, E, F, G and H represent independently –C(R_3)=, –C(R_3)=C(R_4)-,-C(=O)-,-C(=S)-, –O-, -N=, -N(R_3)- or -S-;

Any N may be an N-oxide.

or pharmaceutically acceptable salts, hydrates or solvates of such compounds.

Claim 7. (Currently amended) A compound according to claim 1 or 2 having the formula I-F



I-F

Wherein

P and Q are each independently selected and denote a cyclolkyl, an aryl or heteroaryl group of formula



,



,



,



,



R_3, R_4, R_5, R_6, and R_7 independently are hydrogen, halogen, -CN, nitro, C_1-C_6-alkyl, C_3-C_6-cycloalkyl, C_3-C_7-cycloalkylalkyl, C_2-C_6-alkenyl, C_2-C_6-alkynyl, halo-C_1-C_6-alkyl, -heteroaryl, heteroarylalkyl, arylalkyl, aryl, -OR_8, -NR_8R_9, -$C(=NR_{10})NR_8R_9$, $N(=NR_{10})NR_8R_9$, -NR_8COR_9, $NR_8CO_2R_9$, $NR_8SO_2R_9$, -$NR_{10}CO$ NR_8R_9, -SR_8, -$S(=O)R_8$, -$S(=O)_2R_8$, -$S(=O)_2NR_8R_9$, -$C(=O)R_8$, ~~-$C(=O)_2R_8$,~~ -$C(=O)NR_8R_9$, -$C(=NR_8)R_9$, or $C(=NOR_8)R_9$ substituents; wherein optionally two substituents are combined to the intervening atoms to form a bicyclic heterocycloalkyl, aryl or heteroaryl ring; wherein each ring is optionally further substituted with 1-5 independent halogen, -CN, C_1-C_6-alkyl, -$O(C_0$-C_6-alkyl), -$O(C_3$-C_7-cycloalkylalkyl), -O(aryl), -O(heteroaryl), -$O(C_1$-C_3-alkylaryl), -$O(C_1$-C_3-alkylheteroaryl), –$N(C_0$-C_6-alkyl)(C_0-C_3-alkylaryl) or –$N(C_0$-C_6-alkyl)(C_0-C_3-alkylheteroaryl) groups;

R_8, R_9, R_{10} each independently is hydrogen, C_1-C_6-alkyl, C_3-C_6-cycloalkyl, C_3-C_7-cycloalkylalkyl, C_2-C_6-alkenyl, C_2-C_6-alkynyl, halo-C_1-C_6-alkyl, heterocycloalkyl, heteroaryl, heteroarylalkyl, arylalkyl or aryl; any of which is optionally substituted with 1-5 independent halogen, -CN, C_1-C_6-alkyl, -$O(C_0$-C_6-alkyl), -$O(C_3$-C_7-cycloalkylalkyl), -O(aryl), -O(heteroaryl), -$N(C_0$-C_6-alkyl)(C_0-C_6-alkyl),-$N(C_0$-C_6-alkyl)(C_3-C_7-cycloalkyl) or –$N(C_0$-C_6-alkyl)(aryl) substituents;

D, E, F, G and H represent independently –$C(R_3)$=, –$C(R_3)$=$C(R_4)$-,-C(=O)-,-C(=S)-, –O-, -N=, -$N(R_3)$- or -S-;

Any N may be an N-oxide.

or pharmaceutically acceptable salts, hydrates or solvates of such compounds.

Claim 8. (Currently amended) A compound according to claim 1 having the formula I-G



I-G

Wherein

R_1 and R_2 represent independently hydrogen, C_1-C_6-alkyl, C_2-C_6-alkenyl, C_2-C_6-alkynyl, arylalkyl, heteroarylalkyl, hydroxy, amino, aminoalkyl, hydroxyalkyl, C_1-C_6-alkoxy or R_1 and R_2 together can form a C_3-C_7-cycloalkyl ring, a carbonyl bond C=O or a carbon double bond;

P and Q are each independently selected and denote a cycloalkyl, an aryl or heteroaryl group of formula



R_3, R_4, R_5, R_6, and R_7 independently are hydrogen, halogen, -CN, nitro, C_1-C_6-alkyl, C_3-C_6-cycloalkyl, C_3-C_7-cycloalkylalkyl, C_1-C_6-alkenyl, C_1-C_6-alkynyl, halo-C_1-C_6-alkyl, -heteroaryl, heteroarylalkyl, arylalkyl, aryl, -OR_8, -NR_8R_9, -$C(=NR_{10})NR_8R_9$, $N(=NR_{10})NR_8R_9$, -NR_8COR_9, $NR_8CO_2R_9$, $NR_8SO_2R_9$, -$NR_{10}CO$ NR_8R_9, -SR_8, -$S(=O)R_8$, -$S(=O)_2R_8$, -$S(=O)_2NR_8R_9$, -$C(=O)R_8$, ~~-$C(=O)_2R_8$,~~ -$C(=O)NR_8R_9$, -$C(=NR_8)R_9$, or $C(=NOR_8)R_9$ substituents; wherein optionally two substituents are combined to the intervening atoms to form a bicyclic aryl or heteroaryl ring; wherein each ring is optionally further substituted with 1-5 independent halogen, -CN, C_1-C_6-alkyl, -O(C_0-C_6-alkyl), -O(C_3-C_7-cycloalkylalkyl), -O(aryl), -O(heteroaryl), -O(C_1-C_3-alkylaryl), -O(C_1-C_3-alkylheteroaryl), –N(C_0-C_6-alkyl)(C_0-C_3-alkylaryl) or –N(C_0-C_6-alkyl)(C_0-C_3-alkylheteroaryl) groups;

R_8, R_9, R_{10} each independently is hydrogen, C_1-C_6-alkyl, C_3-C_6-cycloalkyl, C_3-C_7-cycloalkylalkyl, C_2-C_6-alkenyl, C_2-C_6-alkynyl, halo-C_1-C_6-alkyl, heteroaryl, heteroarylalkyl, arylalkyl or aryl; any of which is optionally substituted with 1-5 independent halogen, -CN, C_1-C_6-alkyl, -O(C_0-C_6-alkyl), -O(C_3-C_7-cycloalkylalkyl), -O(aryl), -O(heteroaryl), -N(C_0-C_6-alkyl)(C_0-C_6-alkyl),-N(C_0-C_6-alkyl)(C_3-C_7-cycloalkyl) or –N(C_0-C_6-alkyl)(aryl) substituents;

D, E, F, G and H represent independently –C(R_3)=, –C(R_3)=C(R_4)-,-C(=O)-,-C(=S)-, –O-, -N=, -N(R_3)- or -S-;

A is azo –N=N-, ethyl, ethenyl, ethynyl, -NR_8C(=O)-, NR_8S(=O)$_2$-, -C(=O)NR_8-, -S-, -S(=O)-, -S(=O)$_2$-, -S(=O)$_2$NR_8-, -C(=O)-O-, -O-C(=O)-, -C(=NR_8)NR_9-, C(=NOR_8)NR_9- , -NR_8C(=NOR_9)-, =N-O-, -O-N=CH- or a group aryl or heteroaryl of formula



R_3, R_4, R_5 and R_6 independently are as defined above;
D, E, F, G and H independently represent a carbon group, oxygen, nitrogen, sulphur or a double bond;

B represents a single bond, -C(=O)-C_0-C_2-alkyl-, -C(=O)-C_2-C_6-alkenyl-, -C(=O)-C_2-C_6-alkynyl-, -C(=O)-O-, -C(=O)NR_8-C_0-C_2-alkyl-, -C(=NR_8)NR_9-S(=O)-C_0-C_2-alkyl-, -S(=O)$_2$-C_0-C_2-alkyl-, -S(=O)$_2$NR_8-C_0-C_2-alkyl-, C(=NR_8)-C_0-C_2-alkyl-, -C(=NOR_8)-C_0-C_2-alkyl- or -C(=NOR_8)NR_9-C_0-C_2-alkyl-;
R_8 and R_9, independently are as defined above;

J represents –C(R_{11}, R_{12}), –O-, -N(R_{11})- or -S-;
R_{11}, R_{12} independently are hydrogen, C_1-C_6-alkyl, C_3-C_6-cycloalkyl, C_3-C_7-cycloalkylalkyl, C_2-C_6-alkenyl, C_2-C_6-alkynyl, halo-C_1-C_6-alkyl, heteroaryl, heteroarylalkyl, arylalkyl or aryl; any of which is optionally substituted with 1-5 independent halogen, -CN, C_1-C_6-alkyl, -O(C_0-C_6-alkyl), -O(C_3-C_7-cycloalkylalkyl), -O(aryl), -O(heteroaryl), -N(C_0-C_6-alkyl)(C_0-C_6-alkyl),-N(C_0-C_6-alkyl)(C_3-C_7-cycloalkyl) or –N(C_0-C_6-alkyl)(aryl) substituents;

Any N may be an N-oxide;

or pharmaceutically acceptable salts, hydrates or solvates of such compounds.

Claim 9. (Currently amended) A compound according to claim 1 or 8 having the formula I-H



I-H

Wherein

R_1 and R_2 represent independently hydrogen, C_1-C_6-alkyl, C_2-C_6-alkenyl, C_2-C_6-alkynyl, arylalkyl, heteroarylalkyl, hydroxy, amino, aminoalkyl, hydroxyalkyl, C_1-C_6-alkoxy or R_1 and R_2 together can form a C_3-C_7-cycloalkyl ring, a carbonyl bond C=O or a carbon double bond ;

P and Q are each independently selected and denote a cycloalkyl, an aryl or heteroaryl group of formula



R_3, R_4, R_5, R_6, and R_7 independently are hydrogen, halogen, -CN, nitro, C_1-C_6-alkyl, C_3-C_6-cycloalkyl, C_3-C_7-cycloalkylalkyl, C_2-C_6-alkenyl, C_2-C_6-alkynyl, halo-C_1-C_6-alkyl, heteroaryl, heteroarylalkyl, arylalkyl, aryl, $-OR_8$, $-NR_8R_9$, $-C(=NR_{10})NR_8R_9$, $N(=NR_{10})NR_8R_9$, $-NR_8COR_9$, $NR_8CO_2R_9$, $NR_8SO_2R_9$, $-NR_{10}CO\ NR_8R_9$, $-SR_8$, $-S(=O)R_8$, $-S(=O)_2R_8$, $-S(=O)_2NR_8R_9$, $-C(=O)R_8$, ~~$-C(=O)_2R_8$~~, $-C(=O)NR_8R_9$, $-C(=NR_8)R_9$, or $C(=NOR_8)R_9$ substituents; wherein optionally two substituents are combined to the intervening atoms to form a bicyclic aryl or heteroaryl ring; wherein each ring is optionally further substituted with 1-5 independent halogen,

-CN, C_1-C_6-alkyl, -O(C_0-C_6-alkyl), -O(C_3-C_7-cycloalkylalkyl), -O(aryl), -O(heteroaryl), -O(C_1-C_3-alkylaryl), -O(C_1-C_3-alkylheteroaryl), –N(C_0-C_6-alkyl)(C_0-C_3-alkylaryl) or –N(C_0-C_6-alkyl)(C_0-C_3-alkylheteroaryl) groups;

R_8, R_9, R_{10} each independently is hydrogen, C_1-C_6-alkyl, C_3-C_6-cycloalkyl, C_3-C_7-cycloalkylalkyl, C_2-C_6-alkenyl, C_2-C_6-alkynyl, halo-C_1-C_6-alkyl, heteroaryl, heteroarylalkyl, arylalkyl or aryl; any of which is optionally substituted with 1-5 independent halogen, -CN, C_1-C_6-alkyl, -O(C_0-C_6-alkyl), -O(C_3-C_7-cycloalkylalkyl), -O(aryl), -O(heteroaryl), -N(C_0-C_6-alkyl)(C_0-C_6-alkyl),-N(C_0-C_6-alkyl)(C_3-C_7-cycloalkyl) or –N(C_0-C_6-alkyl)(aryl) substituents;

D, E, F, G and H in P & Q represent independently –C(R_3)=, –C(R_3)=C(R_4)-,-C(=O)-,-C(=S)-, –O-, -N=, -N(R_3)- or -S-;

D,E and G in A are independently as defined for A in claim 1;

B represents a single bond, -C(=O)-C_0-C_2-alkyl-, -C(=O)-C_2-C_6-alkenyl-, -C(=O)-C_2-C_6-alkynyl-, -C(=O)-O-, -C(=O)NR_8-C_0-C_2-alkyl-, -C(=NR_8)NR_9-S(=O)-C_0-C_2-alkyl-, -S(=O)$_2$-C_0-C_2-alkyl-, -S(=O)$_2$NR_8-C_0-C_2-alkyl-, C(=NR_8)-C_0-C_2-alkyl-, -C(=NOR_8)-C_0-C_2-alkyl- or -C(=NOR_8)NR_9-C_0-C_2-alkyl-;
R_8 and R_9, independently are as defined above;

J represents –C(R_{11}, R_{12}), –O-, -N(R_{11})- or -S-;
R_{11}, R_{12} independently are hydrogen, C_1-C_6-alkyl, C_3-C_6-cycloalkyl, C_3-C_7-cycloalkylalkyl, C_2-C_6-alkenyl, C_2-C_6-alkynyl, halo-C_1-C_6-alkyl, heteroaryl, heteroarylalkyl, arylalkyl or aryl; any of which is optionally substituted with 1-5 independent halogen, -CN, C_1-C_6-alkyl, -O(C_0-C_6-alkyl), -O(C_3-C_7-cycloalkylalkyl), -O(aryl), -O(heteroaryl), -N(C_0-C_6-alkyl)(C_0-C_6-alkyl),-N(C_0-C_6-alkyl)(C_3-C_7-cycloalkyl) or –N(C_0-C_6-alkyl)(aryl) substituents;

Any N may be an N-oxide;

or pharmaceutically acceptable salts, hydrates or solvates of such compounds.

Claim 10. (Currently amended) A compound according to claim 1 or 8 having the formula I-I



I-I

Wherein

R_1 and R_2 represent independently hydrogen, C_1-C_6-alkyl, C_2-C_6-alkenyl, C_2-C_6-alkynyl, arylalkyl, heteroarylalkyl, hydroxy, hydroxyalkyl, C_1-C_6-alkoxy or R_1 and R_2 together can form a carbonyl bond C=O or a carbon double bond ;

P and Q are each independently selected and denote a cycloalkyl, an aryl or heteroaryl group of formula



R_3, R_4, R_5, R_6, and R_7 independently are hydrogen, halogen, -CN, nitro, C_1-C_6-alkyl, C_3-C_6-cycloalkyl, C_3-C_7-cycloalkylalkyl, C_2-C_6-alkenyl, C_2-C_6-alkynyl, halo-C_1-C_6-alkyl, heteroaryl, heteroarylalkyl, arylalkyl, aryl, -OR_8, -NR_8R_9, -$C(=NR_{10})NR_8R_9$, $N(=NR_{10})NR_8R_9$, -NR_8COR_9, $NR_8CO_2R_9$, $NR_8SO_2R_9$, -$NR_{10}CO$ NR_8R_9, -SR_8, -$S(=O)R_8$, -$S(=O)_2R_8$, -$S(=O)_2NR_8R_9$, -$C(=O)R_8$, ~~-$C(=O)_2R_8$,~~ -$C(=O)NR_8R_9$, -$C(=NR_8)R_9$, or $C(=NOR_8)R_9$ substituents; wherein optionally two substituents are combined to the intervening atoms to form a bicyclic aryl or heteroaryl ring; wherein each ring is optionally further substituted with 1-5 independent halogen, -CN, C_1-C_6-alkyl, -$O(C_0$-C_6-alkyl), -$O(C_3$-C_7-cycloalkylalkyl), -O(aryl), -O(heteroaryl), -$O(C_1$-C_3-alkylaryl), -$O(C_1$-C_3-alkylheteroaryl), –$N(C_0$-C_6-alkyl)(C_0-C_3-alkylaryl) or –$N(C_0$-C_6-alkyl)(C_0-C_3-alkylheteroaryl) groups;

R_8, R_9, R_{10} each independently is hydrogen, C_1-C_6-alkyl, C_3-C_6-cycloalkyl, C_3-C_7-cycloalkylalkyl, C_2-C_6-alkenyl, C_2-C_6-alkynyl, halo-C_1-C_6-alkyl, heteroaryl, heteroarylalkyl, arylalkyl or aryl; any of which is optionally substituted with 1-5 independent halogen, -CN, C_1-C_6-alkyl, -O(C_0-C_6-alkyl), -O(C_3-C_7-cycloalkylalkyl), -O(aryl), -O(heteroaryl), -N(C_0-C_6-alkyl)(C_0-C_6-alkyl),-N(C_0-C_6-alkyl)(C_3-C_7-cycloalkyl) or –N(C_0-C_6-alkyl)(aryl) substituents;

D, E, F, G and H represent independently –C(R_3)=, –C(R_3)=C(R_4)-,-C(=O)-,-C(=S)-, –O-, -N=, -N(R_3)- or -S-;

B represents a single bond, -C(=O)-C_0-C_2-alkyl-, -C(=O)-C_2-C_6-alkenyl-, -C(=O)-C_2-C_6-alkynyl-, -C(=O)-O-, -C(=O)NR_8-C_0-C_2-alkyl-, -C(=NR_8)NR_9-S(=O)-C_0-C_2-alkyl-, -S(=O)$_2$-C_0-C_2-alkyl-, -S(=O)$_2$NR_8-C_0-C_2-alkyl-, C(=NR_8)-C_0-C_2-alkyl-, -C(=NOR_8)-C_0-C_2-alkyl- or -C(=NOR_8)NR_9-C_0-C_2-alkyl-;
R_8 and R_9, independently are as defined above;

J represents –C(R_{11}, R_{12}), –O-, -N(R_{11})- or -S-;
R_{11}, R_{12} independently are hydrogen, C_1-C_6-alkyl, C_3-C_6-cycloalkyl, C_3-C_7-cycloalkylalkyl, C_2-C_6-alkenyl, C_2-C_6-alkynyl, halo-C_1-C_6-alkyl, heteroaryl, heteroarylalkyl, arylalkyl or aryl; any of which is optionally substituted with 1-5 independent halogen, -CN, C_1-C_6-alkyl, -O(C_0-C_6-alkyl), -O(C_3-C_7-cycloalkylalkyl), -O(aryl), -O(heteroaryl), -N(C_0-C_6-alkyl)(C_0-C_6-alkyl),-N(C_0-C_6-alkyl)(C_3-C_7-cycloalkyl) or –N(C_0-C_6-alkyl)(aryl) substituents;

Any N may be an N-oxide;

or pharmaceutically acceptable salts, hydrates or solvates of such compounds.

Claim 11. (Currently amended) A compound according to claim 1 or 8 having the formula I-J



I-J

Wherein

P and Q are each independently selected and denote a cycloalkyl, an aryl or heteroaryl group of formula



R_3, R_4, R_5, R_6, and R_7 independently are hydrogen, halogen, -CN, nitro, C_1-C_6-alkyl, C_3-C_6-cycloalkyl, C_3-C_7-cycloalkylalkyl, C_2-C_6-alkenyl, C_2-C_6-alkynyl, halo-C_1-C_6-alkyl, heteroaryl, heteroarylalkyl, arylalkyl, aryl, -OR_8, -NR_8R_9, -$C(=NR_{10})NR_8R_9$, $N(=NR_{10})NR_8R_9$, -NR_8COR_9, $NR_8CO_2R_9$, $NR_8SO_2R_9$, -$NR_{10}CO$ NR_8R_9, -SR_8, -$S(=O)R_8$, -$S(=O)_2R_8$, -$S(=O)_2NR_8R_9$, -$C(=O)R_8$, ~~-$C(=O)_2R_8$,~~ -$C(=O)NR_8R_9$, -$C(=NR_8)R_9$, or $C(=NOR_8)R_9$ substituents; wherein optionally two substituents are combined to the intervening atoms to form a bicyclic aryl or heteroaryl ring; wherein each ring is optionally further substituted with 1-5 independent halogen, -CN, C_1-C_6-alkyl, -$O(C_0$-C_6-alkyl), -$O(C_3$-C_7-cycloalkylalkyl), -O(aryl), -O(heteroaryl), -$O(C_1$-C_3-alkylaryl), -$O(C_1$-C_3-alkylheteroaryl), –$N(C_0$-C_6-alkyl)(C_0-C_3-alkylaryl) or –$N(C_0$-C_6-alkyl)(C_0-C_3-alkylheteroaryl) groups;

R_8, R_9, R_{10} each independently is hydrogen, C_1-C_6-alkyl, C_3-C_6-cycloalkyl, C_3-C_7-cycloalkylalkyl, C_2-C_6-alkenyl, C_2-C_6-alkynyl, halo-C_1-C_6-alkyl, heteroaryl, heteroarylalkyl, arylalkyl or aryl; any of which is optionally substituted with 1-5 independent halogen, -CN, C_1-C_6-alkyl, -$O(C_0$-C_6-alkyl), -$O(C_3$-C_7-cycloalkylalkyl), -O(aryl), -O(heteroaryl), -$N(C_0$-C_6-alkyl)(C_0-C_6-alkyl),-$N(C_0$-C_6-alkyl)(C_3-C_7-cycloalkyl) or –$N(C_0$-C_6-alkyl)(aryl) substituents;

D, E, F, G and H represent independently –C(R_3)=, –C(R_3)=C(R_4)-,-C(=O)-,-C(=S)-, –O-, -N=, -N(R_3)- or -S-;

J represents –C(R_{11}, R_{12}), –O-, -N(R_{11})- or -S-;

R_{11}, R_{12} independently are hydrogen, C_1-C_6-alkyl, C_3-C_6-cycloalkyl, C_3-C_7-cycloalkylalkyl, C_2-C_6-alkenyl, C_2-C_6-alkynyl, halo-C_1-C_6-alkyl, heteroaryl, heteroarylalkyl, arylalkyl or aryl; any of which is optionally substituted with 1-5 independent halogen, -CN, C_1-C_6-alkyl, -O(C_0-C_6-alkyl), -O(C_3-C_7-cycloalkylalkyl), -O(aryl), -O(heteroaryl), -N(C_0-C_6-alkyl)(C_0-C_6-alkyl),-N(C_0-C_6-alkyl)(C_3-C_7-cycloalkyl) or –N(C_0-C_6-alkyl)(aryl) substituents;

Any N may be an N-oxide;

or pharmaceutically acceptable salts, hydrates or solvates of such compounds.

Claim 12. (Currently amended) A compound according to claim 1 or 8 having the formula I-K



I-K

Wherein

P and Q are each independently selected and denote a cycloalkyl, an aryl or heteroaryl group of formula



R_3, R_4, R_5, R_6, and R_7 independently are hydrogen, halogen, -CN, nitro, C_1-C_6-alkyl, C_3-C_6-cycloalkyl, C_3-C_7-cycloalkylalkyl, C_2-C_6-alkenyl, C_2-C_6-alkynyl, halo-C_1-C_6-

alkyl, heteroaryl, heteroarylalkyl, arylalkyl, aryl, $-OR_8$, $-NR_8R_9$, $-C(=NR_{10})NR_8R_9$, $N(=NR_{10})NR_8R_9$, $-NR_8COR_9$, $NR_8CO_2R_9$, $NR_8SO_2R_9$, $-NR_{10}CO\ NR_8R_9$, $-SR_8$, $-S(=O)R_8$, $-S(=O)_2R_8$, $-S(=O)_2NR_8R_9$, $-C(=O)R_8$, ~~$-C(=O)_2R_8$~~, $-C(=O)NR_8R_9$, $-C(=NR_8)R_9$, or $C(=NOR_8)R_9$ substituents; wherein optionally two substituents are combined to the intervening atoms to form a bicyclic aryl or heteroaryl ring; wherein each ring is optionally further substituted with 1-5 independent halogen, -CN, C_1-C_6-alkyl, $-O(C_0$-C_6-alkyl), $-O(C_3$-C_7-cycloalkylalkyl), -O(aryl), -O(heteroaryl), $-O(C_1$-C_3-alkylaryl), $-O(C_1$-C_3-alkylheteroaryl), $-N(C_0$-C_6-alkyl)(C_0-C_3-alkylaryl) or $-N(C_0$-C_6-alkyl)(C_0-C_3-alkylheteroaryl) groups;

R_8, R_9, R_{10} each independently is hydrogen, C_1-C_6-alkyl, C_3-C_6-cycloalkyl, C_3-C_7-cycloalkylalkyl, C_2-C_6-alkenyl, C_2-C_6-alkynyl, halo-C_1-C_6-alkyl, heteroaryl, heteroarylalkyl, arylalkyl or aryl; any of which is optionally substituted with 1-5 independent halogen, -CN, C_1-C_6-alkyl, $-O(C_0$-C_6-alkyl), $-O(C_3$-C_7-cycloalkylalkyl), -O(aryl), -O(heteroaryl), $-N(C_0$-C_6-alkyl)(C_0-C_6-alkyl),$-N(C_0$-C_6-alkyl)(C_3-C_7-cycloalkyl) or $-N(C_0$-C_6-alkyl)(aryl) substituents;

D, E, F, G and H represent independently $-C(R_3)=$, $-C(R_3)=C(R_4)-$,$-C(=O)-$,-C(=S)-, –O-, -N=, $-N(R_3)-$ or -S-;

J represents $-C(R_{11}, R_{12})$, –O-, $-N(R_{11})-$ or -S-;
R_{11}, R_{12} independently are hydrogen, C_1-C_6-alkyl, C_3-C_6-cycloalkyl, C_3-C_7-cycloalkylalkyl, C_2-C_6-alkenyl, C_2-C_6-alkynyl, halo-C_1-C_6-alkyl, heteroaryl, heteroarylalkyl, arylalkyl or aryl; any of which is optionally substituted with 1-5 independent halogen, -CN, C_1-C_6-alkyl, $-O(C_0$-C_6-alkyl), $-O(C_3$-C_7-cycloalkylalkyl), -O(aryl), -O(heteroaryl), $-N(C_0$-C_6-alkyl)(C_0-C_6-alkyl),$-N(C_0$-C_6-alkyl)(C_3-C_7-cycloalkyl) or $-N(C_0$-C_6-alkyl)(aryl) substituents;

Any N may be an N-oxide;

or pharmaceutically acceptable salts, hydrates or solvates of such compounds.

Claim 13. (Currently amended) A compound according to claim 1 or 8 having the formula I-L



I-L

Wherein

P and Q are each independently selected and denote a cycloalkyl, an aryl or heteroaryl group of formula



R_3, R_4, R_5, R_6, and R_7 independently are hydrogen, halogen, -CN, nitro, C_1-C_6-alkyl, C_3-C_6-cycloalkyl, C_3-C_7-cycloalkylalkyl, C_2-C_6-alkenyl, C_2-C_6-alkynyl, halo-C_1-C_6-alkyl, heteroaryl, heteroarylalkyl, arylalkyl, aryl, -OR_8, -NR_8R_9, -$C(=NR_{10})NR_8R_9$, $N(=NR_{10})NR_8R_9$, -NR_8COR_9, $NR_8CO_2R_9$, $NR_8SO_2R_9$, -$NR_{10}CO$ NR_8R_9, -SR_8, -$S(=O)R_8$, -$S(=O)_2R_8$, -$S(=O)_2NR_8R_9$, -$C(=O)R_8$, ~~-$C(=O)_2R_8$,~~ -$C(=O)NR_8R_9$, -$C(=NR_8)R_9$, or $C(=NOR_8)R_9$ substituents; wherein optionally two substituents are combined to the intervening atoms to form a bicyclic aryl or heteroaryl ring; wherein each ring is optionally further substituted with 1-5 independent halogen, -CN, C_1-C_6-alkyl, -$O(C_0$-C_6-alkyl), -$O(C_3$-C_7-cycloalkylalkyl), -O(aryl), -O(heteroaryl), -$O(C_1$-C_3-alkylaryl), -$O(C_1$-C_3-alkylheteroaryl), –$N(C_0$-C_6-alkyl)(C_0-C_3-alkylaryl) or –$N(C_0$-C_6-alkyl)(C_0-C_3-alkylheteroaryl) groups;

R_8, R_9, R_{10} each independently is hydrogen, C_1-C_6-alkyl, C_3-C_6-cycloalkyl, C_3-C_7-cycloalkylalkyl, C_2-C_6-alkenyl, C_2-C_6-alkynyl, halo-C_1-C_6-alkyl, heteroaryl, heteroarylalkyl, arylalkyl or aryl; any of which is optionally substituted with 1-5 independent halogen, -CN, C_1-C_6-alkyl, -$O(C_0$-C_6-alkyl), -$O(C_3$-C_7-cycloalkylalkyl), -O(aryl), -O(heteroaryl), -$N(C_0$-C_6-alkyl)(C_0-C_6-alkyl),-$N(C_0$-C_6-alkyl)(C_3-C_7-cycloalkyl) or –$N(C_0$-C_6-alkyl)(aryl) substituents;

D, E, F, G and H represent independently –C(R_3)=, –C(R_3)=C(R_4)-,-C(=O)-,-C(=S)-, –O-, -N=, -N(R_3)- or -S-;

J represents –C(R_{11}, R_{12}), –O-, -N(R_{11})- or -S-;

R_{11}, R_{12} independently are hydrogen, C_1-C_6-alkyl, C_3-C_6-cycloalkyl, C_3-C_7-cycloalkylalkyl, C_2-C_6-alkenyl, C_2-C_6-alkynyl, halo-C_1-C_6-alkyl, heteroaryl, heteroarylalkyl, arylalkyl or aryl; any of which is optionally substituted with 1-5 independent halogen, -CN, C_1-C_6-alkyl, -O(C_0-C_6-alkyl), -O(C_3-C_7-cycloalkylalkyl), -O(aryl), -O(heteroaryl), -N(C_0-C_6-alkyl)(C_0-C_6-alkyl),-N(C_0-C_6-alkyl)(C_3-C_7-cycloalkyl) or –N(C_0-C_6-alkyl)(aryl) substituents;

Any N may be an N-oxide;

or pharmaceutically acceptable salts, hydrates or solvates of such compounds.

Claim 14. (Currently amended) A compound according to claim 1 or 8 having the formula I-M



I-M

Wherein

P and Q are each independently selected and denote a cycloalkyl, an aryl or heteroaryl group of formula



R_3, R_4, R_5, R_6, and R_7 independently are hydrogen, halogen, -CN, nitro, C_1-C_6-alkyl, C_3-C_6-cycloalkyl, C_3-C_7-cycloalkylalkyl, C_2-C_6-alkenyl, C_2-C_6-alkynyl, halo-C_1-C_6-alkyl, heteroaryl, heteroarylalkyl, arylalkyl, aryl, -OR_8, -NR_8R_9, -$C(=NR_{10})NR_8R_9$, $N(=NR_{10})NR_8R_9$, -NR_8COR_9, $NR_8CO_2R_9$, $NR_8SO_2R_9$, -$NR_{10}CO$ NR_8R_9, -SR_8, -$S(=O)R_8$, -$S(=O)_2R_8$, -$S(=O)_2NR_8R_9$, -$C(=O)R_8$, ~~-$C(=O)_2R_8$,~~ -$C(=O)NR_8R_9$, -$C(=NR_8)R_9$, or $C(=NOR_8)R_9$ substituents; wherein optionally two substituents are combined to the intervening atoms to form a bicyclic aryl or heteroaryl ring; wherein each ring is optionally further substituted with 1-5 independent halogen, -CN, C_1-C_6-alkyl, -$O(C_0$-C_6-alkyl), -$O(C_3$-C_7-cycloalkylalkyl), -O(aryl), -O(heteroaryl), -$O(C_1$-C_3-alkylaryl), -$O(C_1$-C_3-alkylheteroaryl), –$N(C_0$-C_6-alkyl)(C_0-C_3-alkylaryl) or –$N(C_0$-C_6-alkyl)(C_0-C_3-alkylheteroaryl) groups;

R_8, R_9, R_{10} each independently is hydrogen, C_1-C_6-alkyl, C_3-C_6-cycloalkyl, C_3-C_7-cycloalkylalkyl, C_2-C_6-alkenyl, C_2-C_6-alkynyl, halo-C_1-C_6-alkyl, heteroaryl, heteroarylalkyl, arylalkyl or aryl; any of which is optionally substituted with 1-5 independent halogen, -CN, C_1-C_6-alkyl, -$O(C_0$-C_6-alkyl), -$O(C_3$-C_7-cycloalkylalkyl), -O(aryl), -O(heteroaryl), -$N(C_0$-C_6-alkyl)(C_0-C_6-alkyl),-$N(C_0$-C_6-alkyl)(C_3-C_7-cycloalkyl) or –$N(C_0$-C_6-alkyl)(aryl) substituents;

D, E, F, G and H represent independently –$C(R_3)$=, –$C(R_3)=C(R_4)$-,-C(=O)-,-C(=S)-, –O-, -N=, -$N(R_3)$- or -S-;

J represents –$C(R_{11}, R_{12})$, –O-, -$N(R_{11})$- or -S-;

R_{11}, R_{12} independently are hydrogen, C_1-C_6-alkyl, C_3-C_6-cycloalkyl, C_3-C_7-cycloalkylalkyl, C_2-C_6-alkenyl, C_2-C_6-alkynyl, halo-C_1-C_6-alkyl, heteroaryl, heteroarylalkyl, arylalkyl or aryl; any of which is optionally substituted with 1-5 independent halogen, -CN, C_1-C_6-alkyl, -$O(C_0$-C_6-alkyl), -$O(C_3$-C_7-cycloalkylalkyl), -O(aryl), -O(heteroaryl), -$N(C_0$-C_6-alkyl)(C_0-C_6-alkyl),-$N(C_0$-C_6-alkyl)(C_3-C_7-cycloalkyl) or –$N(C_0$-C_6-alkyl)(aryl) substituents;

Any N may be an N-oxide;

or pharmaceutically acceptable salts, hydrates or solvates of such compounds.

Claim 15. (Currently amended) A compound according to claim 1 or 8 having the formula I-N



I-N

Wherein

P and Q are each independently selected and denote a cycloalkyl, an aryl or heteroaryl group of formula



R_3, R_4, R_5, R_6, and R_7 independently are hydrogen, halogen, -CN, nitro, C_1-C_6-alkyl, C_3-C_6-cycloalkyl, C_3-C_7-cycloalkylalkyl, C_2-C_6-alkenyl, C_2-C_6-alkynyl, halo-C_1-C_6-alkyl, heteroaryl, heteroarylalkyl, arylalkyl, aryl, $-OR_8$, $-NR_8R_9$, $-C(=NR_{10})NR_8R_9$, $N(=NR_{10})NR_8R_9$, $-NR_8COR_9$, $NR_8CO_2R_9$, $NR_8SO_2R_9$, $-NR_{10}CO\ NR_8R_9$, $-SR_8$, $-S(=O)R_8$, $-S(=O)_2R_8$, $-S(=O)_2NR_8R_9$, $-C(=O)R_8$, ~~$-C(=O)_2R_8$~~, $-C(=O)NR_8R_9$, $-C(=NR_8)R_9$, or $C(=NOR_8)R_9$ substituents; wherein optionally two substituents are combined to the intervening atoms to form a bicyclic aryl or heteroaryl ring; wherein each ring is optionally further substituted with 1-5 independent halogen, -CN, C_1-C_6-alkyl, $-O(C_0$-C_6-alkyl), $-O(C_3$-C_7-cycloalkylalkyl), -O(aryl), -O(heteroaryl), $-O(C_1$-C_3-alkylaryl), $-O(C_1$-C_3-alkylheteroaryl), $-N(C_0$-C_6-alkyl)(C_0-C_3-alkylaryl) or $-N(C_0$-C_6-alkyl)(C_0-C_3-alkylheteroaryl) groups;

R_8, R_9, R_{10} each independently is hydrogen, C_1-C_6-alkyl, C_3-C_6-cycloalkyl, C_3-C_7-cycloalkylalkyl, C_2-C_6-alkenyl, C_2-C_6-alkynyl, halo-C_1-C_6-alkyl, heteroaryl, heteroarylalkyl, arylalkyl or aryl; any of which is optionally substituted with 1-5 independent halogen, -CN, C_1-C_6-alkyl, $-O(C_0$-C_6-alkyl), $-O(C_3$-C_7-cycloalkylalkyl),

-O(aryl), -O(heteroaryl), -N(C_0-C_6-alkyl)(C_0-C_6-alkyl),-N(C_0-C_6-alkyl)(C_3-C_7-cycloalkyl) or –N(C_0-C_6-alkyl)(aryl) substituents;

D, E, F, G and H represent independently –C(R_3)=, –C(R_3)=C(R_4)-,-C(=O)-,-C(=S)-, –O-, -N=, -N(R_3)- or -S-;

J represents –C(R_{11}, R_{12}), –O-, -N(R_{11})- or -S-;

R_{11}, R_{12} independently are hydrogen, C_1-C_6-alkyl, C_3-C_6-cycloalkyl, C_3-C_7-cycloalkylalkyl, C_2-C_6-alkenyl, C_2-C_6-alkynyl, halo-C_1-C_6-alkyl, heteroaryl, heteroarylalkyl, arylalkyl or aryl; any of which is optionally substituted with 1-5 independent halogen, -CN, C_1-C_6-alkyl, -O(C_0-C_6-alkyl), -O(C_3-C_7-cycloalkylalkyl), -O(aryl), -O(heteroaryl), -N(C_0-C_6-alkyl)(C_0-C_6-alkyl),-N(C_0-C_6-alkyl)(C_3-C_7-cycloalkyl) or –N(C_0-C_6-alkyl)(aryl) substituents;

Any N may be an N-oxide;

or pharmaceutically acceptable salts, hydrates or solvates of such compounds.

Claim 16. (Currently amended) A compound according to claim 1 ~~claims 1 to 15~~, which can exist as optical isomers, wherein said compound is either the racemic mixture or the individual optical isomers.

Claim 17. (Currently amended) A compound according to claim 1 ~~claims 1 to 16~~, wherein said compounds are selected from:

(4-Fluoro-phenyl)-[3-(4-fluoro-phenylethynyl)-piperidin-1-yl]-methanone
(4-Fluoro-phenyl)-{3-[5-(4-fluoro-phenyl)-4H-[1,2,4]triazol-3-yl]-piperidin-1-yl}-methanone
(*S*)-(4-Fluoro-phenyl)-{3-[3-(4-fluoro-phenyl)-[1,2,4]oxadiazol-5-yl]-piperidin-1-yl}-methanone
(S)-(thiophen-2-yl)-{3-[3-(4-fluoro-phenyl)-[1,2,4]oxadiazol-5-yl]-piperidin-1-yl}-methanone
{(S)-3-[3-(4-Fluoro-phenyl)-[1,2,4]oxadiazol-5-yl]-piperidin-1-yl}-(4-methyl-2-pyrazin-2-yl-thiazol-5-yl)-methanone
(2,4-Difluoro-phenyl)-{(S)-3-[3-(4-fluoro-phenyl)-[1,2,4]oxadiazol-5-yl]-piperidin-1-yl}-methanone

{(S)-3-[3-(4-Fluoro-phenyl)-[1,2,4]oxadiazol-5-yl]-piperidin-1-yl}-(3,4,5-trifluoro-phenyl)-methanone
{(S)-3-[3-(4-Fluoro-phenyl)-1,2,4-oxadiazol-5-yl]-piperidin-1-yl}-(5-pyridin-2-yl-thiophen-2-yl)-methanone
Cyclopentyl-{(S)-3-[3-(4-fluoro-phenyl)-[1,2,4]oxadiazol-5-yl]-piperidin-1-yl}-methanone
(3,4-Difluoro-phenyl)-{(S)-3-[3-(4-fluoro-phenyl)-[1,2,4]oxadiazol-5-yl]-piperidin-1-yl}-methanone
Benzothiazol-6-yl-{(S)-3-[3-(4-fluoro-phenyl)-1,2,4-oxadiazol-5-yl]-piperidin-1-yl}-methanone
(3,5-Dimethyl-isoxazol-4-yl)-{(S)-3-[3-(4-fluoro-phenyl)-[1,2,4]oxadiazol-5-yl]-piperidin-1-yl}-methanone
(4-Fluoro-phenyl)-{(S)-3-[3-(2,4,6-trifluoro-phenyl)-[1,2,4]oxadiazol-5-yl]-piperidin-1-yl}-methanone
(4-Fluoro-phenyl)-[(S)-3-(3-pyridin-3-yl-[1,2,4]oxadiazol-5-yl)-piperidin-1-yl]-methanone
(4-Fluoro-phenyl)-[(S)-3-(3-pyridin-4-yl-[1,2,4]oxadiazol-5-yl)-piperidin-1-yl]-methanone
{(S)-3-[3-(2,4-Difluoro-phenyl)-[1,2,4]oxadiazol-5-yl]-piperidin-1-yl}-(4-fluoro-phenyl)-methanone
(4-Fluoro-phenyl)-[(S)-3-(3-p-tolyl-[1,2,4]oxadiazol-5-yl)-piperidin-1-yl]-methanone
(4-Fluoro-phenyl)-{(S)-3-[3-(2-fluoro-phenyl)-[1,2,4]oxadiazol-5-yl]-piperidin-1-yl}-methanone
(4-Fluoro-phenyl)-[(S)-3-(3-pyridin-2-yl-[1,2,4]oxadiazol-5-yl)-piperidin-1-yl]-methanone
(4-Fluoro-phenyl)-{3-[5-(4-fluoro-phenyl)-[1,3,4]oxadiazol-2-yl]-piperidin-1-yl}-methanone
(2-Fluoro-phenyl)-{(S)-3-[2-(3,4-difluoro-phenyl)-1,2,4]oxadiazol-5-yl]-piperidin-1-yl}-methanone
(4-Fluoro-phenyl)-{2-[3-(4-fluoro-phenyl)-[1,2,4]oxadiazol-5-yl]-morpholin-4-yl}-methanone
{(S)-3-[3-(4-Fluoro-phenyl)-[1,2,4]oxadiazol-5-yl]-piperidin-1-yl}-thiophen-3-yl-methanone
(4-Fluoro-phenyl)-[3-(5-phenyl-tetrazol-2-yl)-piperidin-1-yl]-methanone
(4-Fluoro-phenyl)-[(S)-3-(3-phenyl-[1,2,4]oxadiazol-5-yl)-piperidin-1-yl]-methanone
(3,4-Difluoro-phenyl)-[(S)-3-(3-phenyl-[1,2,4]oxadiazol-5-yl)-piperidin-1-yl]-methanone.

Claim 18. (Currently amended) A compound according to claim 1 ~~claims 1 to 16~~, wherein said compounds are selected from:

{3-[3-(4-Methoxy-phenyl)-[1,2,4]oxadiazol-5-yl]-piperidin-1-yl}-phenyl-methanone
{3-[3-(4-Fluoro-phenyl)-[1,2,4]oxadiazol-5-yl]-piperidin-1-yl}-phenyl-methanone
(4-Fluoro-phenyl)-[3-(3-phenyl-[1,2,4]oxadiazol-5-yl)-piperidin-1-yl]-methanone

(3-Fluoro-phenyl)-[3-(3-phenyl-[1,2,4]oxadiazol-5-yl)-piperidin-1-yl]-methanone

(4-Fluoro-phenyl)-{3-[3-(3-fluoro-phenyl)-[1,2,4]oxadiazol-5-yl]-piperidin-1-yl}-methanone

(3-Fluoro-phenyl)-{3-[3-(3-fluoro-phenyl)-[1,2,4]oxadiazol-5-yl]-piperidin-1-yl}-methanone

(4-Fluoro-phenyl)-{3-[3-(4-fluoro-phenyl)-[1,2,4]oxadiazol-5-yl]-piperidin-1-yl}-methanone

(3-Fluoro-phenyl)-{3-[3-(4-fluoro-phenyl)-[1,2,4]oxadiazol-5-yl]-piperidin-1-yl}-methanone

(*R*)-(4-Fluoro-phenyl)-{3-[3-(4-fluoro-phenyl)-[1,2,4]oxadiazol-5-yl]-piperidin-1-yl}-methanone

(4-Fluoro-phenyl)-{3-[5-(4-fluoro-phenyl)-[1,2,4]oxadiazol-3-yl]-piperidin-1-yl}-methanone

(4-Fluoro-phenyl)-{3-[5-(4-fluoro-phenyl)-4-methyl-4H-[1,2,4]triazol-3-yl]-piperidin 1-yl}-methanone

{(S)-3-[3-(4-Fluoro-phenyl)-[1,2,4]oxadiazol-5-yl]-piperidin-1-l}-(2-phenyl-thiazol-4-yl)-methanone

{{(S)-3-[3-(4-Fluoro-phenyl)-[1,2,4]oxadiazol-5-yl]-piperidin-1-yl}-(2-methyl-6-trifluoromethyl-pyridin-3-yl)-methanone

{(S)-3-[3-(4-Fluoro-phenyl)-[1,2,4]oxadiazol-5-yl]-piperidin-1-yl}-[1,2,3]thiadiazol-4-yl-methanone

Benzothiazol-2-yl-{(S)-3-[3-(4-fluoro-phenyl)-[1,2,4]oxadiazol-5-yl]-piperidin-1-yl}-methanone

{(S)-3-[3-(4-Fluoro-phenyl)-[1,2,4]oxadiazol-5-yl]-piperidin-1-yl}-(5-methyl-isoxazol-3-yl)-methanone

(1,5-Dimethyl-1H-pyrazol-3-yl)-{(S)-3-[3-(4-fluoro-phenyl)-[1,2,4]oxadiazol-5-yl]-piperidin-1-yl}-methanone

{(S)-3-[3-(4-Fluoro-phenyl)-[1,2,4]oxadiazol-5-yl]-piperidin-1-yl}-(4-trifluoromethyl-phenyl)-methanone

4-{(S)-3-[3-(4-Fluoro-phenyl)-[1,2,4]oxadiazol-5-yl]-piperidine-1-carbonyl}-benzonitrile

{(S)-3-[3-(4-Fluoro-phenyl)-[1,2,4]oxadiazol-5-yl]-piperidin-1-yl}-isoxazol-5-yl-methanone

(3-Chloro-4-fluoro-phenyl)-{(S)-3-[3-(4-fluoro-phenyl)-[1,2,4]oxadiazol-5-yl]-piperidin-1-yl}-methanone

{(S)-3-[3-(4-Fluoro-phenyl)-[1,2,4]oxadiazol-5-yl]-piperidin-1-yl}-(2-phenyl-2H-pyrazol-3-yl)-methanone

{(S)-3-[3-(4-Fluoro-phenyl)-[1,2,4]oxadiazol-5-yl]-piperidin-1-yl}-(5-methyl-2-phenyl-2H-[1,2,3]triazol-4-yl)-methanone

(4-Fluoro-3-methyl-phenyl)-{(S)-3-[3-(4-fluoro-phenyl)-[1,2,4]oxadiazol-5-yl]-piperidin-1-yl}-methanone

{(S)-3-[3-(4-Fluoro-phenyl)-1,2,4-oxadiazol-5-yl]-piperidin-1-yl}-(3-methyl-thiophen-2-yl)-methanone

{(S)-3-[3-(4-Fluoro-phenyl)-1,2,4-oxadiazol-5-yl]-piperidin-1-yl}-(1-methyl-1H-pyrrol-2-yl)-methanone

{(S)-3-[3-(4-Fluoro-phenyl)-1,2,4-oxadiazol-5-yl]-piperidin-1-yl}-thiazol-2-yl-methanone

{(S)-3-[3-(4-Fluoro-phenyl)-1,2,4-oxadiazol-5-yl]-piperidin-1-yl}-(4-methyl-thiazol-5-yl)-methanone

{(S)-3-[3-(4-Fluoro-phenyl)-1,2,4-oxadiazol-5-yl]-piperidin-1-yl}-(6-morpholin-4-yl-pyridin-3-yl)-methanone

{(S)-3-[3-(4-Fluoro-phenyl)-1,2,4-oxadiazol-5-yl]-piperidin-1-yl}-(1H-indol-5-yl)-methanone

2-(4-Fluoro-phenyl)-1-{(S)-3-[3-(4-fluoro-phenyl)-1,2,4-oxadiazol-5-yl]-piperidin-1-yl}-ethanone

3-(4-Fluoro-phenyl)-1-{(S)-3-[3-(4-fluoro-phenyl)-1,2,4-oxadiazol-5-yl]-piperidin-1-yl}-propan-1-one

{(S)-3-[3-(4-Fluoro-phenyl)-1,2,4-oxadiazol-5-yl]-piperidin-1-yl}-isoquinolin-3-yl-methanone

{(S)-3-[3-(4-Fluoro-phenyl)-1,2,4-oxadiazol-5-yl]-piperidin-1-yl}-quinoxalin-6-yl-methanone

{(S)-3-[3-(4-Fluoro-phenyl)-1,2,4-oxadiazol-5-yl]-piperidin-1-yl}-benzoimidazol-6-yl-methanone

(4-Fluoro-phenyl)-[(S)-3-(3-naphthalen-1-yl-[1,2,4]oxadiazol-5-yl)-piperidin-1-yl]-methanone

{(S)-3-[3-(2,6-Difluoro-phenyl)-[1,2,4]oxadiazol-5-yl]-piperidin-1-yl}-(4-fluoro-phenyl)-methanone

(4-Fluoro-phenyl)-{(S)-3-[3-(2-methoxy-phenyl)-[1,2,4]oxadiazol-5-yl]-piperidin-1-yl}-methanone

(4-Fluoro-phenyl)-[(S)-3-(3-naphthalen-2-yl-[1,2,4]oxadiazol-5-yl)-piperidin-1-yl]-methanone

(4-Fluoro-phenyl)-{3-[5-(4-fluoro-phenyl)-[1,2,4]oxadiazol-3-yl]-piperidin-1-yl}-methanone

(4-Fluoro-phenyl)-{3-[3-(4-fluoro-phenyl)-[1,2,4]oxadiazol-5-yl]-4-methyl-piperazin-1-yl}-methanone

(S)-1-(4-Fluoro-benzoyl)-piperidine-3-carboxylic acid (4-fluoro-phenyl)-amide

(S)-1-(4-Fluoro-benzoyl)-piperidine-3-carboxylic acid (4-fluoro-phenyl)-methyl-amide.

(E)-3-(4-Fluoro-phenyl)-1-{(S)-3-[3-(4-fluoro-phenyl)-[1,2,4]oxadiazol-5-yl]-piperidin-1-yl}-propenone

1-(4-{(S)-3-[3-(4-Fluoro-phenyl)-[1,2,4]oxadiazol-5-yl]-piperidine-1-carbonyl}-piperidin-1-yl)-ethanone

{(S)-3-[3-(4-Fluoro-phenyl)-[1,2,4]oxadiazol-5-yl]-piperidin-1-yl}-(4-imidazol-1-yl-phenyl)-methanone

(4-Fluoro-phenyl)-{(S)-3-[3-(4-nitro-phenyl)-[1,2,4]oxadiazol-5-yl]-piperidin-1-yl}-methanone

(3,4-Difluoro-phenyl)-{(S)-3-[3-(4-nitro-phenyl)-[1,2,4]oxadiazol-5-yl]-piperidin-1-yl}-methanone.

Claim 19. (Currently amended) A compound according to claim 1 ~~claims 1 to 16~~, wherein said compounds are selected from:

(4-fluorophenyl)-{(S)-3-[5-(4-fluorophenyl)isoxazol-3-yl]piperidin-1-yl}methanone

(4-fluorophenyl)-{(S)- 3-[5-(4-fluorophenyl)-1H-imidazol-2-yl]piperidin-1-yl)methanone

(4-fluorophenyl)-{(S)- 3-[4-(4-fluorophenyl)-1H-imidazol-1-yl]piperidin-1-yl}methanone

(4-fluorophenyl)-{(S)- 3-[4-(4-fluorophenyl)-1H-pyrazol-1-yl]piperidin-1-yl }methanone

N-(1-(4-fluorobenzoyl)piperidin-3-yl)-4-fluorobenzamid

(2-Fluoro-phenyl)-{3-[2-(4-fluoro-phenyl)-oxazol-5-yl]-piperidin-1-yl}-methanone

(2-Fluoro-phenyl)-{3-[5-(4-fluoro-phenyl)-oxazol-2-yl]-piperidin-1-yl}-methanone

(2-Fluoro-phenyl)-{3-[5-(4-fluoro-phenyl)-thiazol-2-yl]-piperidin-1-yl}-methanone

(2-Fluoro-phenyl)-{3-[2-(4-fluoro-phenyl)-thiazol-5-yl]-piperidin-1-yl}-methanone

(2-Fluoro-phenyl)-{3-[5-(4-fluoro-phenyl)-[1,3,4]thiadiazol-2-yl]-piperidin-1-yl}-methanone

(2-Fluoro-phenyl)-{3-[5-(4-fluoro-phenyl)-[1,2,4]oxadiazol-3-yl]-piperidin-1-yl}-methanone

(2-fluorophenyl)(3-(5-(4-fluorophenyl)isoxazol-3-yl)piperidin-1-yl)methanone

(2-fluorophenyl)(3-(5-(4-fluorophenyl)-1H-imidazol-2-yl)piperidin-1-yl)methanone

(2-fluorophenyl)(3-(4-(4-fluorophenyl)-1H-imidazol-1-yl)piperidin-1-yl)methanone

(2-fluorophenyl)(3-(4-(4-fluorophenyl)-1H-pyrazol-1-yl)piperidin-1-yl)methanone

N-(1-(4-fluorobenzoyl)piperidin-3-yl)-2-fluorobenzamid

(2-Fluoro-phenyl)-{3-[2-(3,4-fluoro-phenyl)-oxazol-5-yl]-piperidin-1-yl}-methanone

(2-Fluoro-phenyl)-{3-[5-(3,4-fluoro-phenyl)-oxazol-2-yl]-piperidin-1-yl}-methanone

(2-Fluoro-phenyl)-{3-[5-(3,4-fluoro-phenyl)-thiazol-2-yl]-piperidin-1-yl}-methanone

(2-Fluoro-phenyl)-{3-[2-(3,4-fluoro-phenyl)-thiazol-5-yl]-piperidin-1-yl}-methanone

(2-Fluoro-phenyl)-{3-[5-(3,4-fluoro-phenyl)-[1,3,4]thiadiazol-2-yl]-piperidin-1-yl}-methanone

(2-Fluoro-phenyl)-{3-[5-(3,4-fluoro-phenyl)-[1,2,4]oxadiazol-3-yl]-piperidin-1-yl}-methanone

(2-fluorophenyl)(3-(5-(3,4-fluorophenyl)isoxazol-3-yl)piperidin-1-yl)methanone

(2-fluorophenyl)(3-(5-(3,4-fluorophenyl)-1H-imidazol-2-yl)piperidin-1-yl)methanone

(2-fluorophenyl)(3-(4-(3,4-fluorophenyl)-1H-imidazol-1-yl)piperidin-1-yl)methanone

(2-fluorophenyl)(3-(4-(3,4-fluorophenyl)-1H-pyrazol-1-yl)piperidin-1-yl)methanone

N-(1-(3,4-fluorobenzoyl)piperidin-3-yl)-2-fluorobenzamid.

Claim 20. (Currently amended) A pharmaceutical composition comprising a therapeutically effective amount of a compound according to claim 1 ~~claims 1 to 19~~ and pharmaceutically acceptable carriers and/or excipients.

Claim 21. (Currently amended) A method of treating or preventing a condition in a mammal, including a human, the treatment or prevention of which is affected or facilitated by the neuromodulatory effect of mGluR5 allosteric modulators, comprising administering to a mammal in need of such treatment or prevention, an effective amount of a compound/composition according to claim 1 ~~claims 1 to 20~~.

Claim 22. (Currently amended) A method of treating or preventing a condition in a mammal, including a human, the treatment or prevention of which is affected or facilitated by the neuromodulatory effect of mGluR5 positive allosteric modulators (enhancer), comprising administering to a mammal in need of such treatment or prevention, an effective amount of a compound according to claim 1 ~~claims 1 to 20~~.

Claim 23. (Currently amended) A method useful for treating or preventing central nervous system disorders selected from the group consisting of anxiety disorders: Agoraphobia, Generalized Anxiety Disorder (GAD), Obsessive-Compulsive Disorder (OCD), Panic Disorder, Posttraumatic Stress Disorder (PTSD), Social Phobia, Other Phobias, Substance-Induced Anxiety Disorder, comprising administering an effective amount of a compound according to claim 1 ~~claims 1 to 20~~.

Claim 24. (Currently amended) A method useful for treating or preventing central nervous system disorders selected from the group consisting of childhood disorders: Attention-Deficit/Hyperactivity Disorder), comprising administering an effective amount of a compound according to claim 1 ~~claims 1 to 20~~.

Claim 25. (Currently amended) A method useful for treating or preventing central nervous system disorders selected from the group consisting of eating Disorders (Anorexia Nervosa, Bulimia Nervosa), comprising administering an effective amount of a compound according to claim 1 ~~claims 1 to 20~~.

Claim 26. (Currently amended) A method useful for treating or preventing central nervous system disorders selected from the group consisting of mood disorders: Bipolar Disorders (I & II), Cyclothymic Disorder, Depression, Dysthymic Disorder, Major Depressive Disorder, Substance-Induced Mood Disorder, comprising administering an effective amount of a compound according to claim 1 ~~claims 1 to 20~~.

Claim 27. (Currently amended) A method useful for treating or preventing central nervous system disorders selected from the group consisting of psychotic disorders: Schizophrenia, Delusional Disorder, Schizoaffective Disorder, Schizophreniform Disorder, Substance-Induced Psychotic Disorder, comprising administering an effective amount of a compound according to claim 1 ~~claims 1 to 20~~.

Claim 28. (Currently amended) A method useful for treating or preventing central nervous system disorders selected from the group consisting of cognitive disorders: Delirium, Substance-Induced Persisting Delirium, Dementia, Dementia Due to HIV Disease, Dementia Due to Huntington's Disease, Dementia Due to Parkinson's Disease, Dementia of the Alzheimer's Type, Substance-Induced Persisting Dementia, Mild Cognitive Impairment, comprising administering an effective amount of a compound according to claim 1 ~~claims 1 to 20~~.

Claim 29. (Currently amended) A method useful for treating or preventing central nervous system disorders selected from the group consisting of personality disorders: Obsessive-Compulsive Personality Disorder, Schizoid, Schizotypal disorder, comprising administering an effective amount of a compound according to claim 1 ~~claims 1 to 20~~.

Claim 30. (Currently amended) A method useful for treating or preventing central nervous system disorders selected from the group consisting of substance-related disorders: Alcohol abuse, Alcohol dependence, Alcohol withdrawal, Alcohol withdrawal delirium, Alcohol-induced psychotic disorder, Amphetamine dependence, Amphetamine withdrawal, Cocaine dependence, Cocaine withdrawal, Nicotine dependence, Nicotine withdrawal, Opioid dependence, Opioid withdrawal, comprising administering an effective amount of a compound according to claim 1 ~~claims 1 to 20~~.

Claims 31-32. (Cancelled)

Claim 33. (new) A method for treating a mammal suffering from or susceptible to Agoraphobia, Generalized Anxiety Disorder (GAD), Obsessive-Compulsive Disorder (OCD), Panic Disorder, Posttraumatic Stress Disorder (PTSD), Social Phobia, Other Phobias, Substance-Induced Anxiety Disorder, the method comprising administering a compound of claim 1 to the mammal.

Claim 34. (new) A method for treating a mammal suffering from or susceptible to Attention-Deficit/Hyperactivity Disorder, or an Eating disorder, the method comprising administering a compound of claim 1 to the mammal.

Claim 35. (new) A method for treating a mammal suffering from or susceptible to an Eating disorder, the method comprising administering a compound of claim 1 to the mammal.

Claim 36. (new) A method for treating a mammal suffering from or susceptible to Bipolar Disorders (I & II), Cyclothymic Disorder, Depression, Dysthymic Disorder, Major Depressive Disorder, or Substance-Induced Mood Disorder, the method comprising administering a compound of claim 1 to the mammal.

Claim 37. (new) A method for treating a mammal suffering from or susceptible to Schizophrenia, Delusional Disorder, Schizoaffective Disorder, Schizophreniform Disorder, or Substance-Induced Psychotic Disorder, the method comprising administering a compound of claim 1 to the mammal.

Claim 38. (new) A method for treating a mammal suffering from or susceptible to Delirium, Substance-Induced Persisting Delirium, Dementia, Dementia Due to HIV Disease, Dementia Due to Huntington's Disease, Dementia Due to Parkinson's Disease, Dementia of the Alzheimer's Type, Substance-Induced Persisting Dementia, or Mild Cognitive Impairment, the method comprising administering a compound of claim 1 to the mammal.

Claim 39. (new) A method for treating a mammal suffering from or susceptible to Obsessive-Compulsive Personality Disorder, Schizoid, or Schizotypal disorder, the method comprising administering a compound of claim 1 to the mammal.

Claim 40. (new) A method for treating a mammal suffering from or susceptible to Alcohol abuse, Alcohol dependence, Alcohol withdrawal, Alcohol withdrawal delirium, Alcohol-induced psychotic disorder, Amphetamine dependence, Amphetamine withdrawal, Cocaine dependence, Cocaine withdrawal, Nicotine dependence, Nicotine withdrawal, Opioid dependence, or Opioid withdrawal, the method comprising administering a compound of claim 1 to the mammal.

Claim 41. (new) A pharmaceutical composition comprising a compound of claim 1.

Claim 42. (new) A pharmaceutical composition of claim 41 further comprising a pharmaceutically acceptable carrier.

Claim 43. (new) A method to prepare a tracer to for imaging metabotropic glutamate receptors, comprising using a compound of claim 1.